{"id":"gentuximab-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Proteinuria"},{"rate":null,"effect":"Hemorrhage"},{"rate":null,"effect":"Thromboembolism"},{"rate":null,"effect":"Gastrointestinal perforation"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gentuximab binds to VEGF, a key signaling molecule that promotes the growth of new blood vessels supplying tumors. By blocking VEGF, the drug starves tumors of their blood supply, inhibiting tumor growth and metastasis. This anti-angiogenic mechanism is designed to work as a standalone therapy or in combination with chemotherapy in solid tumors.","oneSentence":"Gentuximab is a monoclonal antibody that targets and inhibits vascular endothelial growth factor (VEGF) to suppress tumor angiogenesis and blood vessel formation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:55.183Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT05919381","phase":"PHASE3","title":"Gentuximab Combined With Paclitaxel Compared With Placebo Combined With Paclitaxel for Gastric Adenocarcinoma.","status":"UNKNOWN","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2022-05-30","conditions":"Adenocarcinoma of Stomach","enrollment":752},{"nctId":"NCT04053205","phase":"PHASE1, PHASE2","title":"A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer","status":"UNKNOWN","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2019-08","conditions":"Advanced Gastric or Gastroesophageal Junction Cancer","enrollment":76},{"nctId":"NCT03313219","phase":"PHASE1","title":"Pharmacokinetics and Tolerancebility Studies of Gentuximab Injection in the Treatment ofPatients With Late Recurrence of Metastatic Solid Tumors in China","status":"UNKNOWN","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2017-10-11","conditions":"Solid Tumor","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":595852,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Almonertinib"],"phase":"phase_3","status":"active","brandName":"Gentuximab Injection","genericName":"Gentuximab Injection","companyName":"Changchun GeneScience Pharmaceutical Co., Ltd.","companyId":"changchun-genescience-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gentuximab Injection is being studied in clinical trials for the treatment of adenocarcinoma of the stomach, solid tumors, and advanced gastric or gastroesophageal junction cancer. The exact mechanism of Gentuximab Injection is currently unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}